Study: NCT00556933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - 4 doses
Description: 6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin - 4 doses
Description: 6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.